ALZ Stock Overview
A biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Alzinova AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.88 |
| 52 Week High | SEK 4.12 |
| 52 Week Low | SEK 0.95 |
| Beta | 1.04 |
| 11 Month Change | 185.29% |
| 3 Month Change | 235.06% |
| 1 Year Change | 13.95% |
| 33 Year Change | -49.41% |
| 5 Year Change | -66.55% |
| Change since IPO | -70.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALZ | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 50.4% | -2.4% | -4.3% |
| 1Y | 14.0% | 18.0% | 12.6% |
Return vs Industry: ALZ underperformed the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: ALZ exceeded the Swedish Market which returned 12.6% over the past year.
Price Volatility
| ALZ volatility | |
|---|---|
| ALZ Average Weekly Movement | 18.4% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ALZ's share price has been volatile over the past 3 months.
Volatility Over Time: ALZ's weekly volatility has increased from 13% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5 | n/a | www.alzinova.com |
Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer’s disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study.
Alzinova AB (publ) Fundamentals Summary
| ALZ fundamental statistics | |
|---|---|
| Market cap | SEK 172.78m |
| Earnings (TTM) | -SEK 17.17m |
| Revenue (TTM) | SEK 18.06m |
9.6x
P/S Ratio-10.1x
P/E RatioIs ALZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALZ income statement (TTM) | |
|---|---|
| Revenue | SEK 18.06m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 18.06m |
| Other Expenses | SEK 35.23m |
| Earnings | -SEK 17.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -95.10% |
| Debt/Equity Ratio | 0.7% |
How did ALZ perform over the long term?
See historical performance and comparison